We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: oncology
MedXY News
EnglishTag

oncology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
newsoncologyoral cavity cancer

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer

By MedXY|Dec 21, 2025

A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know
Hematology-Oncologydịch vụ chăm sóc cuối đờihealth services use

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know

By MedXY|Dec 13, 2025

In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea

Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort
Hematology-Oncologyhealth policyMedicare

Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort

By MedXY|Nov 22, 2025

In a population-based Medicare cohort, oncologists preferentially selected higher-clinical-benefit cancer treatments; provider billing margin was not associated with treatment choice, suggesting price or payment reforms that change margins

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial
newscervical cancerclinical trial

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY|Oct 25, 2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise
newscervical cancerLymphadenectomy

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY|Oct 25, 2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope
newsHER2-mutant NSCLConcology

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY|Oct 25, 2025

This article reviews recent clinical trial data showing sevabertinib’s efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained
Clinical Updatesclinical trialsoncology

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

By MedXY|Oct 1, 2025

This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations
newsFDA Approvalsoncology

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations

By MedXY|Sep 30, 2025

Analysis of FDA approvals from 2009–2020 reveals only 29% of next-in-class oncology drugs underwent head-to-head RCTs against originals, with just 22% showing survival benefits, highlighting a need for incentivized comparative trials.

Prev
5 / 5
1…345
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities